The platform enables the targeted injection of hydrogel-cannabinoid-loaded liposomes into the bloodstream or to a specific body part
Corporation () announced Monday that it has achieved positive results following months of tests on its cannabidiol (CBD) loaded liposomal platform technology.
The platform enables the delivery of cannabinoids by injection of hydrogel-cannabinoid-loaded liposomes into the bloodstream or to a specific body part, the Israeli cannabis company said in a statement.
The controlled release of CBD (or other cannabinoids) from the liposomes may allow continuous exposure of the patient to the cannabinoid and decreases the variations of CBD concentration in the blood caused by food intake or other physiological conditions.
READ: Israeli cannabis companies flower on the Canadian Securities Exchange
Moreover, through injection of loaded liposomes, a greater portion of intact CBD can reach its target site, decreasing the total amount of CBD needed to achieve the desired therapeutic effect. The use of the technology is versatile and may be tailored to the development of different cannabinoids, the company said.
InnoCan conducted the tests in conjunction with the Yissum Research and Development Company, the commercial arm of Hebrew University in Jerusalem. Development efforts and tests for the CBD-loaded liposomes were performed over several months and achieved the following results:
High loading of CBD in an amount sufficient for administration of a therapeutic dose. Several types of CBD liposomal formulations were developed having potential of targeting a variety of clinical indications for CBD injection administration. The liposomal formulations may have the potential to enable a controlled-release delivery of injectable CBD."This is a significant milestone and creates the basis for the development of therapeutically meaningful new drugs, based on local injection of CBD, that could have greater efficacy and promote the well-being of patients suffering different ailments," said Chezy Barenholz, head of membrane and liposome research lab at the Hebrew University Hadassah Medical School.
InnCan CEO Iris Bincovich added: "These positive first stage results are a powerful demonstration of the value of our partnership with Hebrew University. Continued test success would provide InnoCan with numerous commercial prospects. We anticipate the completion of the next development stage, within 18 to 24 months."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
